PTGFR

Prostaglandin F2-alpha receptor · P43088 · PTGFR on Sugi Atlas →

35,805 patent compounds predicted against PTGFR, 20,818 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1043898	0.58	17/20
SCHEMBL1043901	0.58	17/20
SCHEMBL1043903	0.58	17/20
Cloprostenol (SCHEMBL123595)	1.00	16/20
Cloprostenol (SCHEMBL123596)	1.00	16/20
Fluprostenol (SCHEMBL230607)	1.00	16/20
Fluprostenol (SCHEMBL635658)	0.98	16/20
Cloprostenol (SCHEMBL28242)	0.84	16/20
SCHEMBL1047070	0.66	16/20
SCHEMBL1047071	0.66	16/20
SCHEMBL1047073	0.66	16/20
SCHEMBL230608	0.65	16/20
SCHEMBL461619	0.62	16/20
SCHEMBL1047119	0.62	16/20
SCHEMBL1047120	0.62	16/20
Tiaprost (SCHEMBL867741)	0.78	15/20
Etiproston (SCHEMBL571117)	0.67	15/20
Fenprostalene (SCHEMBL564040)	0.63	15/20
Travoprost (SCHEMBL93818)	1.00	14/20
Travoprost (SCHEMBL818060)	1.00	14/20

Clinical trials — most relevant to PTGFR by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Type 2 Diabetes Mellitus and Atherosclerosis	PHASE4	UNKNOWN
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD	PHASE4	UNKNOWN
Pharmacogenomics of Antiplatelet Response - I	PHASE4	COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients	PHASE2/PHASE3	UNKNOWN
Addition of Aspirin to Standard of Care in Oral Cancer	PHASE2/PHASE3	COMPLETED
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery	PHASE2	COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC	PHASE1/PHASE2	UNKNOWN
Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction	PHASE2	COMPLETED
Autologous Platelet-Rich Plasma (PRP) and Endometrial Thickness	PHASE2	UNKNOWN
Avastin and Tarceva for Upper Gastrointestinal Cancers	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer	PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	PHASE1	COMPLETED
Vitamin E Supplements in Preventing Cancer in Patients at Risk of Prostate Cancer or Who Have Prostate Cancer	PHASE1	COMPLETED
Study About Patients Using Copper Intrauterine Device	nan	COMPLETED
Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer	nan	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Platelet Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome (HiPPO Trial)	nan	COMPLETED
Progressive Open Angle Glaucoma (OAG) and Ocular Blood Flow	nan	WITHDRAWN
Effect of Post Covid-19 Hypoxia on Placenta of Normal Pregnant Women: A Possible Role of Hypoxia Inducible Factor-1α.	nan	UNKNOWN
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis	nan	UNKNOWN
Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer	nan	COMPLETED
The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term	nan	WITHDRAWN
The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth	nan	WITHDRAWN
Platelet-Rich Plasma for Partial Rotator Cuff Tears	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTGFR binder may also engage these)

Protein	Name	Similarity
P43117	—	1.000	P43117 →
P37289	—	0.995	P37289 →
P43118	—	0.995	P43118 →
Q28905	—	0.995	Q28905 →
P50131	—	0.982	P50131 →
Q95125	—	0.976	Q95125 →
P46069	—	0.974	P46069 →
P30557	—	0.974	P30557 →
P34980	—	0.973	P34980 →
P34979	—	0.973	P34979 →
PTGER3	Prostaglandin E2 receptor EP3 subtype	0.972	landscape →
Q62053	—	0.971	Q62053 →
Q9DDK4	—	0.969	Q9DDK4 →
S1PR1	Sphingosine 1-phosphate receptor 1	0.967	landscape →
O08530	—	0.967	O08530 →
P70263	—	0.966	P70263 →
Q9R261	—	0.965	Q9R261 →
P48303	—	0.964	P48303 →
Q62928	—	0.964	Q62928 →
Q5E9P3	—	0.964	Q5E9P3 →
PTGER2	Prostaglandin E2 receptor EP2 subtype	0.964	landscape →
P47752	—	0.963	P47752 →
Q9Z0U9	—	0.962	Q9Z0U9 →
P52592	—	0.961	P52592 →
Q9XT82	—	0.960	Q9XT82 →
O35932	—	0.960	O35932 →
Q56H79	—	0.957	Q56H79 →
S1PR2	Sphingosine 1-phosphate receptor 2	0.956	landscape →
A5D7K8	—	0.956	A5D7K8 →
Q9PUQ8	—	0.955	Q9PUQ8 →